Australia markets closed

STRAUMANN HOLDING AG Namens-Akt (QS5.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
770.200.00 (0.00%)
As of 8:10AM CEST. Market open.
Full screen
Previous close770.20
Open753.00
Bid0.00 x 5000
Ask0.00 x 5000
Day's range747.00 - 753.00
52-week range747.00 - 770.20
Volume0
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Lumibird: 2020 Full-Year Revenues in Line With Expectations at €126.7m

    Lannion, January 25, 2021 – 5:45pm 2020 full-year revenues in line with expectations at €126.7m on a reported basis (+14.4% YoY and +40.7% in Q4) and €100m like-for-like (-9.7% YoY and +2.1% in Q4) The LUMIBIRD Group, the European leader for laser technologies, is reporting full-year revenues of €126.7m on a reported basis, up 14.4%. The fourth quarter was marked by record revenues of close to €50m, reflecting the return to organic growth (+2.1%) and the contribution from new activities (€13.2m). In the crisis context that affected 2020, full-year organic growth is down -9.7% or approximately -€10.7m, primarily factoring in the reduced level of activity on the MegaJoule contract (-€5.5m) for Photonics1 and the drop in sales linked to the cancellation of major global shows (-€3.2m) for the Medical business. With better visibility concerning its markets and after further strengthening its financial, industrial and commercial capabilities, LUMIBIRD plans to continue moving forward with its organic and external growth strategy to double its revenues (reported basis) by 2023, with average organic annual growth of 8% to 10% and a target EBITDA margin of 20% to 25%. Consolidated revenues (unaudited) Revenues (€m) 2020 2019 Reported change Organic change 1 pro forma 2020 2 First quarter 21.9 24.2 -9.5% -16.7% Second quarter 23.9 27.5 -13.3% -17.2% Third quarter 32.7 24.8 +32.1% -9.9% Fourth quarter 48.2 34.2 +40.7% +2.1% 12 months 126.7 110.7 +14.4% -9.7% 146.4 of which Photonic (formerly Laser) 68.5 71.4 -4.1% -10.6% 68.5 Medical 58.2 39.3 +48.1% -8.0% 77.9 1 Organic change: at constant exchange rates and like-for-like 2 Including Ellex at January 1, 2020 The LUMIBIRD Group’s full-year consolidated revenues for 2020 climbed to €126.7m, up 14.4%. Like-for-like and at constant exchange rates (restated for the acquisitions of Ellex at June 30, 2020, the Essmed Group at July 31, 2020, Optotek Medical at August 31, 2019 and Halo Photonics at December 24, 2019), they are down -9.7% to €100.0m. Including Ellex’s laser and ultrasound activities at January 1, pro-forma 2020 revenues represent €146.4m. The Group is reporting record fourth-quarter revenues of €48.2m, factoring in the contribution from new activities (€13.2m) and positive organic growth (+2.1%) for the first time in the year, against the backdrop of the health and economic crisis. Like-for-like and at constant exchange rates, the Medical division came in stable for the last quarter (-0.5%), while the Photonics division achieved 3.7% growth. With a more detailed analysis, the Industrial and Scientific business continued to be penalized by the closure of many universities and research laboratories, with a 4.4% contraction for the quarter. The Defense / Space business returned to growth (+3.8%), reflecting the combined impact of the planned scaling down of the MegaJoule contract that began in the fourth quarter of 2019 and the ramping up of both new contracts and the non-contracts business. The Lidar Sensors business benefited from the integration of Halo Photonics (€1.8m for the quarter), as well as 14.7% organic growth for the last quarter. Despite the restrictions introduced with the health crisis, the integration of Ellex and the development of commercial and industrial synergies have moved forward as planned, with sales for the new combined structure in line with the budget set, including operations in the United States. LUMIBIRD is approaching 2021 with confidence, backed by an extensive order book, confirming the upturn on the Group’s various markets. Looking ahead to 2023, the Group plans to continue moving forward with its combined organic and external growth strategy with a view to doubling its current revenues (reported basis). Building on its buoyant markets, its capacity for innovation and the impact of its commercial synergies, it is targeting 8% to 10% average organic growth over the next three years. In terms of profitability, looking beyond the expected synergies, the Group’s performance on purchases, supply chain rationalization and growing vertical integration are expected to contribute towards the target for EBITDA margin growth of 20% to 25% from 2021. Next date: 2020 full-year earnings on March 16, 2021 after close of trading LUMIBIRD is one of the world's leading specialists in lasers. With 50 years of experience and a mastering of solid state laser, laser diodes and fiber laser technologies, the Group designs, manufactures and markets high performance lasers for scientific (laboratories and universities), industrial (manufacturing, defense, Lidar sensors) and medical (ophthalmology) markets. Born from the combination of Keopsys Group with Quantel in October 2017, LUMIBIRD has more than 800 employees and over €126 million of consolidated revenues in 2020 and is present in Europe, America and Asia. LUMIBIRD shares are listed on the Euronext Paris B Compartment. FR0000038242 – LBIRD www.lumibird.com Contacts LUMIBIRDMarc Le FlohicChairman and CEOTel. +33(0) 1 69 29 17 00info@lumibird.com LUMIBIRDAude Nomblot-GourhandSecretary General – CFOTel. +33(0) 1 69 29 17 00info@lumibird.com CalyptusMathieu CalleuxInvestors RelationsTel. +33(1) 53 65 37 91lumibird@calyptus.net 1 Previously the “Laser” division Attachment 2010125LumibirdCAFY2020EN

  • GlobeNewswire

    LUMIBIRD CONFIRMS ITS INTEREST IN CILAS

    Lannion, January 21, 2021 – 7:30am LUMIBIRD CONFIRMS ITS INTEREST IN CILAS Following a rumour published in the French newspaper LA TRIBUNE concerning LUMIBIRD's interest in CILAS if the company was to be sold by its shareholders, LUMIBIRD confirms that such an acquisition would be in line with its development strategy. CILAS and LUMIBIRD have highly complementary technology portfolios which together would constitute the European leader in laser technologies for the Defence market, and could thus be the technological partner of major Defence integrators. LUMIBIRD will study the CILAS opportunity with the financial discipline it has always applied in its acquisition strategy. In accordance with its obligations, LUMIBIRD will inform the market should this opportunity materialise. Next date: 2020 full-year revenues and 2023 objectives on January 25, 2021 (after close of trading) LUMIBIRD is one of the world's leading specialists in lasers. With 50 years of experience and a mastering of solid state laser, laser diodes and fiber laser technologies, the Group designs, manufactures and markets high performance lasers for scientific (laboratories and universities), industrial (manufacturing, defense, Lidar sensors) and medical (ophthalmology) markets. Born from the combination of Keopsys Group with Quantel in October 2017, LUMIBIRD has more than 800 employees and over €110 million of revenues in 2019 and is present in Europe, America and Asia. LUMIBIRD shares are listed on the Euronext Paris B Compartment. FR0000038242 – LBIRD www.lumibird.com Contacts LUMIBIRDMarc Le FlohicChairman and CEOTel. +33(0) 1 69 29 17 00info@lumibird.com LUMIBIRDAude Nomblot-GourhandSecretary General – CFOTel. +33(0) 1 69 29 17 00info@lumibird.com CalyptusMathieu CalleuxInvestors RelationsTel. +33(1) 53 65 37 91lumibird@calyptus.net Attachment 210121_LUMIBIRD_CILAS_EN

  • LUmibird: FINANCIAL COMMUNICATIONS AGENDA
    GlobeNewswire

    LUmibird: FINANCIAL COMMUNICATIONS AGENDA

    Lannion, January 5, 2021 – 5:35pmFINANCIAL COMMUNICATIONS AGENDALUMIBIRD [FR0000038242 – LBIRD], the European leader for laser technologies, publishes its financial communications agenda for 2021.  Disclosure date Closed period FY 2020 revenues Monday 25/01/2021*   FY 2020 earnings Tuesday 16/03/2021* from 16/02/2021 to 16/03/2021 included Q1 2021 revenues Monday 26/04/2021*   Annual Shareholders Meeting Tuesday 04/05/2021   H1 2021 revenues Monday 26/07/2021*   H1 2021 earnings Tuesday 21/09/2021* from 22/08/2021 to 21/09/2021 included Q3 2021 revenues Monday 25/10/2021*   *after close of tradingThe agenda is indicative and may be subject to change.Closed periods, prior to the publication of earnings, during which no trading in the Company's shares is permitted, apply to managers, persons assimilated to managers and any person who has access on a regular or occasional basis to inside information of the Company.Next date: 2020 full-year revenues and 2023 objectives on January 25, 2021 after close of trading  LUMIBIRD is one of the world's leading specialists in lasers. With 50 years of experience and a mastering of solid state laser, laser diodes and fiber laser technologies, the Group designs, manufactures and markets high performance lasers for scientific (laboratories and universities), industrial (manufacturing, defense, Lidar sensors) and medical (ophthalmology) markets. Born from the combination of Keopsys Group with Quantel in October 2017, LUMIBIRD has more than 800 employees and over €110 million of revenues in 2019 and is present in Europe, America and Asia.LUMIBIRD shares are listed on the Euronext Paris B Compartment. FR0000038242 – LBIRD   www.lumibird.com ContactsLUMIBIRD Marc Le Flohic Chairman and CEO Tel. +33(0) 1 69 29 17 00 info@lumibird.com LUMIBIRD Aude Nomblot-Gourhand Secretary General – CFO Tel. +33(0) 1 69 29 17 00 info@lumibird.com Calyptus Mathieu Calleux Investors Relations Tel. +33(1) 53 65 37 91 lumibird@calyptus.net  Attachment * 210105_LUMIBIRD_calendrier_comfi_2021_EN